EW

SEC source: 0001225208-20-007585 · doc4.xml · nonDerivative · entry 1

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,374.9256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007578 · doc4.xml · derivative · entry 6

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,606 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007578 · doc4.xml · nonDerivative · entry 3

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,593

SEC source: 0001225208-20-007578 · doc4.xml · nonDerivative · entry 2

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,869

SEC source: 0001225208-20-007578 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,619

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007575 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,029.7761

SEC source: 0001225208-20-007574 · doc4.xml · derivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,206 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007574 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,406.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007573 · doc4.xml · derivative · entry 5

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,587 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007573 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,410.0477

SEC source: 0001225208-20-007573 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,620.0477

SEC source: 0001225208-20-007573 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,668.0477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007572 · doc4.xml · derivative · entry 8

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,343 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007572 · doc4.xml · nonDerivative · entry 3

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,959.5169

SEC source: 0001225208-20-007572 · doc4.xml · nonDerivative · entry 2

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,104.5169

SEC source: 0001225208-20-007572 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,789.5169

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.

SEC source: 0001225208-20-007337 · doc4.xml · derivative · entry 9

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,372 shares

Expires 2020-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019.

SEC source: 0001225208-20-007337 · doc4.xml · nonDerivative · entry 3

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,446.5169

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019.

SEC source: 0001225208-20-007337 · doc4.xml · nonDerivative · entry 2

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,818.5169

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019.

SEC source: 0001225208-20-007336 · doc4.xml · derivative · entry 13

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,850 shares

Expires 2020-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 9

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Living Trust

Disclosed balance after: 891,194

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 8

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,200.82

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 7

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,200.82

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F7 · price: This transaction was executed in multiple trades at prices ranging from $219.43 to $220.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 6

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,698.82

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F6 · price: This transaction was executed in multiple trades at prices ranging from $220.43 to $221.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 5

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,302.82

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F5 · price: This transaction was executed in multiple trades at prices ranging from $217.22 to $218.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 4

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,850.82

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F4 · price: This transaction was executed in multiple trades at prices ranging from $218.24 to $219.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 3

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,750.82

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

F3 · price: This transaction was executed in multiple trades at prices ranging from $221.46 to $221.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-20-007336 · doc4.xml · nonDerivative · entry 2

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,050.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.

SEC source: 0001225208-20-007368 · doc4.xml · derivative · entry 2

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,033

Underlying: Common Stock · 1,033 shares

Expires 2027-05-07

F2 · shares: These options were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

F2 · derivative.exercise_date: These options were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

SEC source: 0001225208-20-007368 · doc4.xml · nonDerivative · entry 1

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,424

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

SEC source: 0001225208-20-007367 · doc4.xml · derivative · entry 3

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,378

Underlying: Common Stock · 1,378 shares

Expires 2027-05-07

F2 · shares: These options were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

F2 · derivative.exercise_date: These options were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

SEC source: 0001225208-20-007367 · doc4.xml · nonDerivative · entry 1

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,056

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

SEC source: 0001225208-20-007365 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,349

F2 · shares: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

SEC source: 0001225208-20-007365 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,004

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

SEC source: 0001225208-20-007364 · doc4.xml · nonDerivative · entry 1

Marsh Martha H. · CIK 0001500281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,054

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

SEC source: 0001225208-20-007363 · doc4.xml · nonDerivative · entry 1

Sequeira Ramona · CIK 0001811081 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,101

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

SEC source: 0001225208-20-007362 · doc4.xml · nonDerivative · entry 1

VALERIANI NICHOLAS J · CIK 0001263149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,096

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

SEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 3

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,446

F2 · shares: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

SEC source: 0001225208-20-007361 · doc4.xml · nonDerivative · entry 2

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,101

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

SEC source: 0001225208-20-007344 · doc4.xml · derivative · entry 2

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700

Underlying: Common Stock · 1,700 shares

Expires 2027-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007344 · doc4.xml · nonDerivative · entry 1

SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,117.7761

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007343 · doc4.xml · derivative · entry 3

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200

Underlying: Common Stock · 1,200 shares

Expires 2027-05-06

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007343 · doc4.xml · derivative · entry 2

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,600

Underlying: Common Stock · 9,600 shares

Expires 2027-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-20-007343 · doc4.xml · nonDerivative · entry 1

WANG HUIMIN · CIK 0001204553 · CVP, Japan & Intercontinental

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,210.9256

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007342 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,425

Underlying: Common Stock · 1,425 shares

Expires 2027-05-06

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007342 · doc4.xml · derivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,500

Underlying: Common Stock · 11,500 shares

Expires 2027-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-20-007342 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,081.0477

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007341 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,300

Underlying: Common Stock · 2,300 shares

Expires 2027-05-06

F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-20-007341 · doc4.xml · derivative · entry 3

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,600

Underlying: Common Stock · 16,600 shares

Expires 2027-05-06

F3 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-20-007341 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · CVP, TAVR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,360.9047

F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.